SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas

PLoS ONE

Volumn 2, Issue 10, 2007, Pages

  Compagno, Daniel ^a   Merle, Carole ^a   Morin, Aurélie ^a   Gilbert, Cristèle ^a   Mathieu, Jacques R R ^a   Bozec, Aline ^b   Mauduit, Claire ^b   Benahmed, Mohammed ^b   Cabon, Florence ^a  

^a CNRS   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ISOPROTEIN; MUTANT PROTEIN; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CASTRATION; CONTROLLED STUDY; DRUG SPECIFICITY; EXPERIMENTAL NEOPLASM; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HORMONAL REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE; PROSTATE CARCINOMA; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; TESTIS; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

MUS;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; GENE SILENCING; HUMANS; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; TESTIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 41549141749     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001006     Document Type: Article

References (53)

1. Heinlein GA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276-308.
2. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, et al. (2004) The androgen axis in recurrent prostate cancer. Clin Cancer Res 10: 440-448.
3. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, et al. (2007) Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer. Cancer Res 67: 5033-5041.
4. Culig Z, Steiner H, Bartsch G, Hobisch A (2005) Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr Relat Cancer 12: 229-244.
5. Scher HI, Sawyers CL (2005) Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis. J Clin Oncol 23: 8253-8261.
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
7. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM (2001) Androgen Receptor Stabilization in Recurrent Prostate Cancer Is Associated with Hypersensitivity to Low Androgen. Cancer Res 61: 2892-2898.
8. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP (2006) Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. PNAS 103: 15969-15974.
9. Guo Z, Dai B, Jiang T, Xu K, Xie Y, et al. (2006) Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10: 309-319.
10. Sirotnak FM, She Y, Khokhar NZ, Hayes P, Gerald W, et al. (2004) Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events. Mol Carcinog 41: 150-163.
11. Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, et al. (2000) Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 80: 1789-1796.
12. Dehm SM, Tindall DJ (2006) Ligand-independent androgen receptor activity is activation function-2 independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem: M605002200.
13. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62: 1008-1013.
14. Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, et al. (2005) Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer 12: 119-134.
15. Furutani T, Takeyama K, Koutoku H, Ito S, Taniguchi N, et al. (2005) A role of androgen receptor protein in cell growth of an androgen-independent prostate cancer cell line. Biosci Biotechnol Biochem 69: 2236-2239.
16. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. The Journal of Steroid Biochemistry and Molecular Biology 96: 251-258.
17. Liao X, Tang S, Thrasher JB, Griebling TL, Li B (2005) Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 4: 505-515.
18. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, et al. (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818.
19. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, et al. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotech 21: 635-637.
20. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, et al. (2003) SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 63: 3919-3922.
21. Samuel CE (2001) Antiviral actions of interferons. Clin Microbiol Rev 14: 778-809.
22. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME (2004) Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22: 1579-1582.
23. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270.
24. Kariko K, Bhuyan P, Capodici J, Weissman D (2004) Small Interfering RNAs Mediate Sequence-Independent Gene Suppression and Induce Immune Activation by Signaling through Toll-Like Receptor 3. J Immunol 172: 6545-6549.
25. Nupponen NN, Wallén MJ, Ponciano D, Robbins CM, Tammela TLJ, et al. (2004) Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/ HPC2, and MSR1 in sporadic prostate cancer. Genes, Chromosomes and Cancer 39: 119-125.
26. Benbrahim-Tallaa L, Tabone E, Tosser-Klopp G, Hatey F, Benahmed M (2002) Glutathione S-transferase alpha expressed in porcine Sertoli cells is under the control of follicle-stimulating hormone and testosterone. Biol Reprod 66: 1734-1742.
27. De Gendt K, Swinnen JV, Saunders PT, Schoonjans L, Dewerchin M, et al. (2004) A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A 101: 1327-1332.
28. Gonzalez-Herrera IG, Prado-Lourenco L, Pileur F, Conte C, Morin A, et al. (2006) Testosterone regulates FGF-2 expression during testis maturation by an IRES-dependent translational mechanism FASEB J 20: 476-478.
29. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, et al. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Research 54: 2577-2581.
30. Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, et al. (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35: 403-409.
31. Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D (2002) Inhibition of Ligand-mediated HER2 Activation in Androgen-independent Prostate Cancer. Cancer Res 62: 5485-5488.
32. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW (2003) Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/ protein kinase B in prostate cancer cells. Clin Cancer Res 9: 2416-2425.
33. Wegiel B, Bjartell A, Ekberg J, Gadaleanu V, Brunhoff C, et al. (2005) A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. 24: 6385-6393.
34. Stewart RJ, Panigrahy D, Flynn E, Folkman J (2001) Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 165: 688-693.
35. Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, et al. (2005) Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res 65: 300-308.
36. Bakin RE, Gioeli D, Bissonette EA, Weber MJ (2003) Attenuation of Ras Signaling Restores Androgen Sensitivity to Hormone-refractory C4-2 Prostate Cancer Cells. Cancer Res 63: 1975-1980.
37. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, et al. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucl Acids Res 33: e179-.
38. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541.
39. Behlke MA (2006) Progress towards in Vivo Use of siRNAs. Mol Ther 13: 644-670.
40. Marques JT, Williams BRG (2005) Activation of the mammalian immune system by siRNAs. Nat Biotech 23: 1399-1405.
41. Persengiev SP, Zhu X, Green MR (2004) Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). Rna 10: 12-18.
42. Duxbury MS, Ito H, Benoit E, Ashley SW, Whang EE (2004) CEACAM6 is a determinant of pancreatic Adenocarcinoma cellular invasiveness. Br J Cancer 91: 1384-1390.
43. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23: 1448-1456.
44. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, et al. (2005) Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 54: 1298-1308.
45. Braasch DA, Paroo Z, Constantinescu A, Ren G, Oz OK, et al. (2004) Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 14: 1139-1143.
46. O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, et al. (1999) c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisensee oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res 5: 3977-3982.
47. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, et al. (1995) Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95: 1814-1823.
48. Duxbury MS, Ashley SW, Whang EE (2005) RNA interference: A mammalian SID-1 homologue enhances siRNA uptake and gene silencing efficacy in human cells. Biochem Biophys Res Commun 331: 459-463.
49. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453.
50. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS (2006) Short Hairpin RNA Knockdown of the Androgen Receptor Attenuates Ligand-Independent Activation and Delays Tumor Progression. Cancer Res 66: 10613-10620.
51. Zhang M, Volpert O, Shi YH, Bouck N (2000) Maspin is an angiogenesis inhibitor. Nat Med 6: 196-199.
52. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, et al. (2001) Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate: Prostate 49: 293-305.
53. Florin A, Maire M, Bozec A, Hellani A, Chater S, et al. (2005) Androgens and postmeiotic germ cells regulate claudin-11 expression in rat Sertoli cells. Endocrinology 146: 1532-1540.